ArticleClinical and translational radiation oncology2026
Integration of quantitative MRI and liver function indices to predict early tumor response after stereotactic body radiotherapy for hepatocellular carcinoma: A prospective study.
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early response assessment following stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) is challenging. We prospectively investigated whether changes in diffusion-weighted magnetic resonance imaging (DWI)-derived apparent diffusion coefficient (ADC), tumor markers, and blood-based indices correlated with an early tumor response. Methods: Nineteen patients with 29 HCC lesions underwent SBRT (40 Gy in four fractions). MRI (T2-weighted imaging, diffusion-weighted imaging/ADC, and gadoxetate disodium-enhanced dynamic contrast imaging) and blood tests were scheduled at baseline and at one and three months following SBRT. Tumor response was also assessed at six months using the modified response evaluation criteria in solid tumors (mRECIST) approach. ΔADC was defined as ADC at three months minus baseline ADC. Inter-observer reproducibility of baseline ADC was evaluated using the single-measure intraclass correlation coefficient (ICC). Results: ΔADC was inversely correlated with changes in tumor size at three months (r = -0.43, p = 0.039). ΔADC correlated with the percent change in des-γ-carboxy prothrombin (PIVKA-II) at three months (r = 0.50, p < 0.01) but not with the percent change in alpha-fetoprotein (AFP, r = 0.14, p > 0.05). Baseline ADC demonstrated good reproducibility (ICC = 0.793; 95% CI, 0.606-0.897). The retention rate of indocyanine green at 15 min and albumin-bilirubin scores remained largely stable throughout the three month period. Conclusion: Early increases in ADC after SBRT of the liver were associated with tumor shrinkage and changes in PIVKA-II, supporting the use of quantitative MRI as an early response biomarker. Larger cohorts with longer follow-up periods are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.